KH-903

重组人血管内皮生长因子受体-抗体融合蛋白（成都康弘生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameKH-903
Drug Alias Name重组人血管内皮生长因子受体-抗体融合蛋白注射液(静脉给药)KH-903
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChengdu Kanghong Biotechnologies Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Kanghong Biotechnologies Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsStomach Neoplasms
Inactive IndicationsSolid tumoursColorectal NeoplasmsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A